Zhaoke Ophthalmology Launches Preservative-Free Glaucoma Drug
I'm PortAI, I can summarize articles.
Zhaoke Ophthalmology Ltd. (HK:6622) has received approval from the National Medical Products Administration for its preservative-free Bimatoprost eye drop, the first of its kind in China. This glaucoma treatment aims to enhance patient comfort and compliance by minimizing long-term side effects associated with preservatives. The launch is significant due to the high prevalence of glaucoma in China, which represents about 25% of the global patient population.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments